Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians
Karen A. Autio, Azeez Farooki, Ilya G. Glezerman, Amelia Chan, Coursen W. Schneider, Hallie C. Barr, Brian M. Seyboth, Lewis J. Kampel, Daniel C. Danila, Dana E. Rathkopf, Susan F. Slovin, Howard I. Scher, Michael J. Morris
Clinical Genitourinary Cancer
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
Vogelhuber M. Feyerabend S. Stenzl A. Suedhoff T. Schulze M. Huebner J. Oberneder R. Wieland W. Mueller S. Eichhorn F. Heinzer H. Schmidt K. Baier M. Ruebel A. Birkholz K. Bakhshandeh-Bath A. Andreesen R. Herr W. Reichle A.Cancer Microenvironment, ArticleCancer Microenvironment, 11 December 2014, 9p
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer
Sonpavde G. Pond G.R. Armstrong A.J. Galsky M.D. Leopold L. Wood B.A. Wang S.-L. Paolini J. Chen I. Chow-Maneval E. Mooney D.J. Lechuga M. Smith M.R. Dror Michaelson M.BJU International, Volume 114, Issue 6, 1 December 2014, Pages E25-E31
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer
Bilen M.A. Johnson M.M. Mathew P. Pagliaro L.C. Araujo J.C. Aparicio A. Corn P.G. Tannir N.M. Wong F.C. Fisch M.J. Logothetis C.J. Tu S.-M.Cancer, Volume 121, Issue 1, 1 January 2015, Pages 69-76
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival
Tait C. Moore D. Hodgson C. Brown M. Morris T. Growcott J. Malone M. Hughes A. Renehan A. Clarke N.W. Dive C.BJU International, Volume 114, Issue 6, 1 December 2014, Pages E70-E73
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Vice Chairman of the Department of Urologic Oncology, as well as Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.